NES-ZIONA, Israel, Feb. 24, 2011 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH), a clinical stage company developing next generation biobetter therapeutic proteins, today announced that company management will give a corporate presentation at the 2011 CITI Global Healthcare Conference, to be held at the Hilton New York Hotel in New York City. The presentation is scheduled for March 2, 2011 at 11:30 am ET.
A live webcast of the company's presentation will be available at the Investors section of PROLOR's website at www.prolor-biotech.com/?CategoryID=215, or at http://www.veracast.com/webcasts/citigroup/healthcare2011/11208295.cfm
An audio replay of the presentation will be available on the PROLOR website approximately one hour after the presentation and will be archived for at least 30 days.
ABOUT PROLOR BIOTECH
PROLOR Biotech, Inc. is a clinical stage biopharmaceutical company applying unique technologies, including its patented CTP technology, primarily to develop longer-acting, proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales. The CTP technology is applicable to virtually all proteins, and PROLOR is currently developing long-acting versions of human growth hormone, which is in Phase II clinical development, and Factor IX, Factor VII, interferon beta and erythropoietin, which are in preclinical development, as well as an anti-obesity peptide and agents for atherosclerosis and rheumatoid arthritis. For more information, visit www.prolor-biotech.com.
|
PROLOR CONTACT: |
MEDIA CONTACT: |
|
|
Shai Novik, President |
Barbara Lindheim |
|
|
PROLOR Biotech, Inc. |
GendeLLindheim BioCom Partners |
|
|
Tel: +1 866 644-7811 |
+1 212 918-4650 |
|
|
Email: [email protected] |
||
SOURCE PROLOR Biotech, Inc.